Wellbeing Digital Sciences Inc. KONEF
0.00 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.000001 Day range 0.000001
0.000001 52-week range 0.00001
- YTD
- 0.00%
- 1 year
- 0.00%
News
proactiveinvestors.com Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) told investors it has struck a deal to sell its wholly-owned KGK Science subsidiary to Cardinal Group Inc for $2 million. The company said…
proactiveinvestors.com Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) reported that its subsidiary KGK Science on behalf of its client Nova Mentis has commenced patient recruitment for its first-of-its-kind, Health…
proactiveinvestors.com Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned KGK Sciences Inc (KGK) subsidiary has applied for a Controlled Substance Dealers License from Health Canada,…
proactiveinvestors.com Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) told investors its subsidiary KGK Science Inc (KGK) has completed preclinical safety studies for its caffeine replacement coffee product, which…
proactiveinvestors.com Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) said its wholly-owned subsidiary KGK Sciences Inc. has received an exemption under Section 56 of the Controlled Drugs and Substances Act.
proactiveinvestors.com Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection letter' from Health Canada, on behalf of client…
proactiveinvestors.com Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly owned subsidiary KGK Science Inc has been awarded an institution-wide cannabis research license for its state-of-the-art…
proactiveinvestors.com Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that a clinical study conducted by wholly-owned subsidiary KGK Science Inc has shown positive results of UP446 supplementation in…
proactiveinvestors.com Wellbeing Digital Sciences subsidiary KGK Science submits psilocybin and Fragile X Syndrome clinical trial application for client Nova Mentis Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly-owned subsidiary KGK Science Inc has submitted a clinical trial application (CTA) on behalf of client Nova Mentis Life…
proactiveinvestors.ca Wellbeing Digital Sciences says Mindscape subsidiary treats its 1,000th patient Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its Mindscape Ketamine & Infusion Therapy, PLLC subsidiary has treated its 1,000th patient with IV Ketamine Therapy for…
proactiveinvestors.com Wellbeing Digital Sciences appoints Mohammad Sharifi to its board of directors Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said it has appointed Mohammad Sharifi to its board of directors, effective November 22, 2022. Sharifi will serve as a member of the Audit…
proactiveinvestors.com Wellbeing Digital Sciences says KGK Science subsidiary inks research services deal with Nova Mentis for Fragile X Syndrome clinical trials Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its wholly-owned KGK Science Inc subsidiary has entered into a research services agreement with Nova Mentis Life Science Corp…
proactiveinvestors.ca Wellbeing Digital Sciences says KGK Science subsidiary study successfully delivers CBD and THC through the skin Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its wholly-owned subsidiary KGK Science Inc has completed an open label study, in which Gefion Canada GT4 technology was used…
proactiveinvestors.com Wellbeing Digital Sciences and its subsidiary KGK Sciences hail Alberta government's move to regulate psychedelics use Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) and its wholly-owned subsidiary KGK Sciences Inc have announced that they applaud the efforts by the Alberta government to draw up a plan to…
proactiveinvestors.com Wellbeing Digital Sciences subsidiary KGK Sciences to submit psilocybin microdose capsule formulation to Health Canada Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its subsidiary KGK Sciences Inc has completed the chemistry, manufacturing, and controls (CMC) package to be used in support of a Phase…
proactiveinvestors.ca Wellbeing Digital Sciences to add three well-established pain management facilities to its clinical ecosystem Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc has announced that it has entered into a letter of intent to add three clinics into the company's clinical ecosystem, supporting its…
proactiveinvestors.com Wellbeing Digital Sciences says subsidiary KGK Sciences opens new clinical research centre in Ontario Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has opened its new clinical research center in London, Ontario, with the aim of…
proactiveinvestors.com Wellbeing Digital Sciences posts fiscal 4Q results; projects significant revenue from research and consulting contracts Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said that its revenue in the fourth quarter ended July 31, 2022, rose 2.5% year-over-year, adding that it expects significant revenue in the…
proactiveinvestors.com Wellbeing Digital Sciences says subsidiary KGK Sciences wins FDA's highest safety rating for ProGo ingredient on behalf of client Hofseth BioCare Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc says its wholly-owned subsidiary KGK Sciences Inc, on behalf of its client Hofseth BioCare ASA (HBC), has received a no-objection…
proactiveinvestors.com Wellbeing Digital Sciences says subsidiary IRP Health's new Toronto clinic has received approval from Veterans Affairs Canada for its Reactivation program Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its subsidiary IRP Health Ltd has received approval from Veterans Affairs Canada for its multidisciplinary Reactivation-branded therapy…